Harvard Bioscience (HBIO) Current Deferred Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Current Deferred Revenue data on file, last reported at $3.8 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $3.8 million, up 10.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (up 10.42% YoY), and the FY2025 annual result was $3.4 million, down 9.43% from the prior year.
• Current Deferred Revenue rose to $3.8 million in Q1 2026 per HBIO's latest filing, from $3.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $4.5 million in Q4 2023 and troughed at $3.2 million in Q3 2025.
• A 5-year average of $3.8 million and a median of $3.8 million in 2026 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 33.77% in 2023, then declined 21.9% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $3.4 million in 2022, then soared by 33.77% to $4.5 million in 2023, then slipped by 15.57% to $3.8 million in 2024, then decreased by 9.43% to $3.4 million in 2025, then rose by 9.78% to $3.8 million in 2026.
• Business Quant data shows HBIO's Current Deferred Revenue at $3.8 million in Q1 2026, $3.4 million in Q4 2025, and $3.2 million in Q3 2025.